218 related articles for article (PubMed ID: 3674579)
1. Theophylline absorption from two sustained-release products. Implications for therapeutic drug monitoring.
Rogers RJ; Wiener MB; Hill MR; Szefler SJ
Am Rev Respir Dis; 1987 Nov; 136(5):1168-73. PubMed ID: 3674579
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system.
González MA; Kisicki J; Straughn AB
Clin Ther; 1994; 16(4):686-92. PubMed ID: 7982257
[TBL] [Abstract][Full Text] [Related]
3. Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl.
Hurwitz A; Karim A; Burns TS
J Clin Pharmacol; 1987 Nov; 27(11):855-61. PubMed ID: 3429692
[TBL] [Abstract][Full Text] [Related]
4. Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium.
Rojanasthien N; Kovjiriyapan K; Manorot M; Pothirat C
Asian Pac J Allergy Immunol; 2001 Jun; 19(2):69-78. PubMed ID: 11699723
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of theophylline chronokinetics for asthmatic children.
Smolensky MH; Scott PH; McGovern JP
Prog Clin Biol Res; 1987; 227B():259-70. PubMed ID: 3628336
[TBL] [Abstract][Full Text] [Related]
6. Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men.
Dockhorn RJ; Cefali EA; Straughn AB
Ann Allergy; 1994 Mar; 72(3):218-22. PubMed ID: 8129214
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of four slow-release theophylline formulations in the beagle dog.
Koritz GD; McKiernan BC; Neff-Davis CA; Munsiff IJ
J Vet Pharmacol Ther; 1986 Sep; 9(3):293-302. PubMed ID: 3761420
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a new sustained-release theophylline preparation, TheoBeads, with Theo-Dur tablets in children with asthma.
Welch MJ; Orgel HA; Meltzer EO; Kemp JP; Gawchik S; Rooklin AR; Tinkelman DG
J Asthma; 1988; 25(5):269-74. PubMed ID: 3182591
[TBL] [Abstract][Full Text] [Related]
9. Sustained-release theophylline. Pharmacokinetic and therapeutic comparison of two preparations.
Menendez R; Kelly HW; Howick J; McWilliams BC
Am J Dis Child; 1983 May; 137(5):469-73. PubMed ID: 6846276
[TBL] [Abstract][Full Text] [Related]
10. Theophylline QID, TID, BID and now QD? A report on 24-hour dosing with slow-release theophylline formulations with emphasis on analyses of data used to obtain Food and Drug Administration approval for Theo-24.
Weinberger MM
Pharmacotherapy; 1984; 4(4):181-98. PubMed ID: 6483637
[TBL] [Abstract][Full Text] [Related]
11. Assessing the efficacy and safety of q. d. theophylline therapy: a multicenter study.
Dockhorn RJ; Green AW; Green E
Ann Allergy; 1985 Nov; 55(5):658-64. PubMed ID: 2865917
[TBL] [Abstract][Full Text] [Related]
12. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
Steinijans VW; Zech K; Fischer R
Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
[TBL] [Abstract][Full Text] [Related]
13. Oral bioavailability of slow-release theophylline from unencapsulated beads in preschool children with chronic asthma.
Vaughan LM; Milavetz G; Weinberger MM; Smith GD; Harris JB
Ther Drug Monit; 1988; 10(4):395-400. PubMed ID: 3059587
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic equivalence of a generic slow-release theophylline tablet.
Hendeles L; Breton AL; Beaty R; Harman E
Pharmacotherapy; 1995; 15(1):26-35. PubMed ID: 7739942
[TBL] [Abstract][Full Text] [Related]
15. Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur).
Oosterhuis B; Brannan MD; Groen H; Peeters PA; Hempenius J; Radwanski E; Nomeir AA; Affrime MB; Jonkman JH
Ann Allergy Asthma Immunol; 1995 Aug; 75(2):157-61. PubMed ID: 7648380
[TBL] [Abstract][Full Text] [Related]
16. Absorption of theophylline from enteric coated and sustained release formulations in fasted and non-fasted subjects.
Osman MA; Patel RB; Irwin DS; Welling PG
Biopharm Drug Dispos; 1983; 4(1):63-72. PubMed ID: 6839003
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of day-night differences in serum theophylline concentration with special reference to Theo-Dur.
Smolensky MH; Scott PH; Kramer WG
J Allergy Clin Immunol; 1986 Oct; 78(4 Pt 2):716-22. PubMed ID: 3771961
[TBL] [Abstract][Full Text] [Related]
18. The influence of enteral feedings on sustained-release theophylline absorption.
Plezia PM; Thornley SM; Kramer TH; Armstrong EP
Pharmacotherapy; 1990; 10(5):356-61. PubMed ID: 2122422
[TBL] [Abstract][Full Text] [Related]
19. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.
Hendeles L; Iafrate RP; Weinberger M
Clin Pharmacokinet; 1984; 9(2):95-135. PubMed ID: 6370542
[TBL] [Abstract][Full Text] [Related]
20. Effect of once daily and twice daily sustained release theophylline formulations on daytime variation of bronchial hyperresponsiveness in asthmatic patients.
Ferrari M; Olivieri M; Lampronti G; Bonazza L; Biasin C; Nacci P; Talamini G; Lo Cascio V
Thorax; 1997 Nov; 52(11):969-74. PubMed ID: 9487345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
